Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026.

GlobeNewsWire • Feb 12, 2026

Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced that the Company is participating in the 44th Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2025. “As the fourth quarter progressed, we were pleased to see that member engagement has paced favorably as compared to the guidance we issued in November,” said Pete Anevski, Progyny's Chief Executive Officer.

GlobeNewsWire • Jan 12, 2026

Progyny, Inc. (PGNY) Soars to 52-Week High, Time to Cash Out?

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Jan 9, 2026

3 Medical Service Industry Stocks Set to Tackle Workforce Challenges

Medical services stocks like MEDP, EHAB and PGNY benefit from tech-driven care models even as staffing gaps pressure margins.

Zacks Investment Research • Jan 9, 2026

Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Dec 23, 2025

Progyny (PGNY) Upgraded to Buy: Here's What You Should Know

Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Dec 15, 2025

CEO Peter Anevski Buys $1.9 Million of Progyny Stock: Should Investors Buy Too?

CEO Anevski now owns $17 million worth of Progyny. Progyny's stock popped roughly 8% the day of the announcement.

The Motley Fool • Dec 2, 2025

Is Progyny (PGNY) a Solid Growth Stock? 3 Reasons to Think "Yes"

Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Nov 24, 2025

New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in family building solutions, today announced new men's health research exploring experiences and views on fertility. The findings shed light on how men in the U.S. view their role in the fertility journey and the barriers that prevent many from getting the care they need for successful conception.

GlobeNewsWire • Nov 20, 2025